

With respective opportunities associated and held by our affiliates, Oncology Will Be The Strategic Pillar For Future Growth, And Fosun Pharma Is Increasing Strategic Pipeline In Non-oncology Areas

PCC	IND	Phase 1	Phase 2	Phase 3	Filing	Approved
FKC211 (FOLR1 CAR-T) EOC	FCN-338 (BCL-2) AML/MDS	YP01001 (VEGFR,FGFR,RET) Solid Tumor	FH1701 (MEK1/2) NF1-Pediatric, LGG, LCH & ECD-Adult, LCH- Pediatric, AVM	FS-1502 (HER2 ADC) 2-4L BC	Avatrombopag (TPO) ITP	FKC876 (CD19 CAR-T) 2L&3L DLBCL
CWB005双抗 (EPO-R) GC/Pancreatic tumor	FCN159 (MEK) Pediatric LCH	FCN-338 (BCL-2) CLL/SLL, NHL(MCL)	FS-1502 (HER2 ADC) 2/3L GC/GEJ, Combo PD- 1 1L GC/GEJ	FH1701 (MEK1/2) NF1-Adult	Tenapanor (NHE-3) ESRD-HD	Avatrombopag (TPO) CLDT
XS-02 (CHK1) Solid tumor	SurVaxM (survivin) GBM	FH2001 (PD-L1/FGFR) Advanced Solid Tumor	SAF-189 (ALK/ROS1) ROS1+NSCLC	SAF-189 (ALK/ROS1) ALK+NSCLC	RT002 (DaxibotulinumtoxinA) Glabellar Line	mRNA XBB. 1.5 COVID-19-Adult Macao
VS-S103 (GLP-1R/GCG- R /GIP-R) T2DM/Obesity/NASH	VT-101 Solid tumor	XH-S003 (Factor B) Immunology	FCN-338 (BCL-2) AML/MDS	FCN-437 (CDK4/6) Late-stage BC 1L, 2L	RT002 (DaxibotulinumtoxinA) Cervical Dystonia	Tenapanor(NHE-3) HK IBS-C
	XS-03 (PLK1) Solid tumor	SZEY-2108 (penicillin- binding protein) CRE	CWB001 Long-acting EPO CKD	FKC-876 (CD19 CAR-T) iNHL	mRNA XBB. 1.5 COVID-19-Adult HK	
	XS-04 (IRAK/BTK) Hematology	Tenapanor(NHE-3) IBS-C		FKC-889 (CD19 CAR-T) MCL, ALL		
	XH-S002 (FXIa) CV & Hematology	PA-824 MDR Tuberculosis		Opicapone (COMT) Parkinson's Disease		
	FH2201(QPCTL) Solid Tumor			ET-26 Anesthesia		
	XH-S004 (DPP1) Immunology			Fortacin Premature Ejaculation		
	OP0595 (β Lactam enzyme) Adult G- Bacterial Infection Grafalon (rabbit IgG) SCT					
	FCN-016 (ROCK) Glaucoma					

Note: 1. CLDT: thrombocytopenia caused by chronic liver

■ Oncology & Hematology
 ■ Immunology
 ■ Chronic disease
 ■ Central Nervous System
 ■ Others